A Phase 3 interventional study of Adalimumab and Methotrexate in Plaque Psoriasis, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-09-25.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.
Among the 48 studies testing adalimumab in Psoriasis, this one is the 29th largest by enrollment, is one of 4 that started in 2010, is one of 26 in phase 3, and was the 16th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
Mabscale, LLC · Sites in Russian Federation
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ages 4–17
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 4 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 27 · Phase 4 11
First in 2003; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 114 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 148 across the 48 interventional studies. Of the 41 that completed or were terminated, 27 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 48 have an industry lead sponsor. The 10 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
79 studies in Psoriasis by AbbVie: 2 open now, 6 under way, 1 of them phase 3. Of 71 finished, 42 (59%) have results posted.
Among the 79 studies in Psoriasis by AbbVie, this one is the 33rd largest by enrollment of the 48 interventional ones that give a count, is one of 7 that started in 2010, is one of 31 in phase 3, and was the 16th registered.
AbbVie’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 48 studies testing adalimumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
This study will compare how well adalimumab works versus methotrexate (MTX) in children with moderate to severe psoriasis in the short term. It will also study how safe and how well adalimumab works in the long term and how long disease response can be maintained after stopping therapy.
The study had a 30-day screening period and a multi-period study design, as described below:
Period A - Primary Treatment Phase: Participants were randomized to receive adalimumab 0.8 mg/kg, adalimumab 0.4 mg/kg, or MTX in 1:1:1 ratio for 16 weeks.
Period B - Treatment Withdrawal Phase: Responders were withdrawn from active treatment and monitored for loss of disease control for up to 36 weeks.
Period C - Re-Treatment Phase: Participants who had experienced loss of disease control in Period B were re-treated with adalimumab for 16 weeks.
Period D - Long-Term Follow-Up Phase: Participants received adalimumab or were observed off-treatment (if disease remained under control) for 52 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject must need systemic treatment to control his/her disease and meet one of the following:
PASI > 10 and at least one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Period A participants received a single subcutaneous loading dose of adalimumab 0.4 mg/kg (up to a maximum of 20 mg) at Week 0 followed by every other week dosing beginning at Week 1. To maintain the blind, participants also received weekly dosing of methotrexate placebo tablets. Participants who were non-responders in Period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.4 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.4 mg/kg eow.
Biological: Adalimumab · Drug: Placebo to Methotrexate
In Period A participants received a single subcutaneous loading dose of adalimumab 0.8 mg/kg (up to a maximum of 40 mg) at Week 0 followed by every other week dosing beginning at Week 1. To maintain the blind, participants also received weekly dosing of methotrexate placebo tablets. Participants who were non-responders in Period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.8 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.8 mg/kg eow.
Biological: Adalimumab · Drug: Placebo to Methotrexate
Participants received 0.1 mg/kg methotrexate at Baseline (Week 0), and up to 0.4 mg/kg weekly (maximum dose of 25 mg/week) in Period A. Participants also received adalimumab placebo as a single subcutaneous loading dose at Week 0, followed by every other week (eow) dosing from Week 1. Participants who were non-responders in period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.8 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.8 mg/kg eow.
Drug: Methotrexate · Biological: Placebo to Adalimumab
Adalimumab by subcutaneous injection every other week (eow)
Also known as: ABT-D2E7, Humira
Methotrexate 0.1 mg/kg at Week 0 and up to 0.4 mg/kg per week (maximum dose of 25 mg/week) orally.
A single subcutaneous loading dose at Week 0 followed by eow dosing beginning at Week 1.
Orally once a week
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 75 Response at Week 16
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in PASI score at Week 16.
Time frame: Baseline and Week 16
Percentage of Participants Achieving a Physician's Global Assessment of Disease Activity (PGA) of "Cleared" (0) or "Minimal" (1) at Week 16
The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: * 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; * 1 (Minimal): Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation; * 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; * 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; * 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; * 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) or minimal (1) is reported.
Time frame: Week 16
Percentage of Participants Who Achieved a PASI 90 Response at Week 16
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 90 response is at least a 90% reduction (improvement) from Baseline in PASI score at Week 16.
Time frame: Baseline and Week 16
Percentage of Participants Who Achieved a PASI 100 Response at Week 16
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 100 response is a 100% reduction (improvement) from Baseline in PASI score at Week 16.
Time frame: Baseline and Week 16
Change From Baseline in the Children's Dermatology Life Quality Index (CDLQI) Score at Week 16
The Children's Dermatology Life Quality Index (CDLQI) is a 10-item questionnaire to measure the quality of life in children aged from 4 to 16 years. Each question is scored from 0 (not at all) to 3 (very much). The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
Time frame: Baseline and Week 16
Change From Baseline in the Pediatric Quality of Life Inventory (PedsQL) Score at Week 16
The PedsQL Measurement Model measures health-related quality of life (HRQOL) in children and adolescents. The 23-item PedsQL Generic Core Scale includes Physical, Emotional, Social, School Functioning dimensions. Each item is scored from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL; the total score therefore ranges from 0 (worst) to 100 (best).
Time frame: Baseline and Week 16
Percentage of Participants Achieving a PGA of "Cleared" (0) or "Minimal" (1) Upon Re-Treatment in Period C
The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; 1 (Minimal): Occasional fine scale over \< 5% of lesions, faint erythema, minimal plaque elevation; 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) or minimal (1) is reported.
Time frame: Period C, Week 16
Time to Loss of Disease Control for Participants Who Entered Period B
Loss of disease control was defined as a worsening of PGA scores in comparison to Week 16 of Period A by at least 2 grades after treatment withdrawal. The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. Scores range from 0 (no evidence of scaling, erythema, or plaque elevation) to 5 (very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation). Participants who did not lose disease control in period B continued off drug into period D and were observed off-drug until they finally lost disease control or until the end of the 52 weeks of period D.
Time frame: Period B (36 weeks) and Period D (52 weeks)
Percentage of Participants Achieving a PGA of "Cleared" (0) or "Minimal" (1) Over Time
The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; 1 (Minimal): Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation; 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) or minimal (1) is reported.
Time frame: Period A, Weeks 4, 8 and 11, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52
Percentage of Participants Achieving a PGA of "Cleared" (0) Over Time
The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; 1 (Minimal): Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation; 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) is reported.
Time frame: Period A, Weeks 4, 8, 11 and 16, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52
Percentage of Participants Who Achieved a PASI 50 Response Over Time
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 50 response is at least a 50% reduction (improvement) from Baseline in PASI score.
Time frame: Baseline, Period A, Weeks 4, 8, 11 and 16, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52
Percentage of Participants Who Achieved a PASI 75 Response Over Time
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 75 response is at least a 75% reduction (improvement) from Baseline in PASI score.
Time frame: Baseline, Period A, Weeks 4, 8, and 11, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52
Percentage of Participants Who Achieved a PASI 90 Response Over Time
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 90 response is at least a 90% reduction (improvement) from Baseline in PASI score.
Time frame: Baseline, Period A, Weeks 4, 8 and 11, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52
Percentage of Participants Who Achieved a PASI 100 Response Over Time
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 100 response is a 100% reduction (improvement) from Baseline in PASI score.
Time frame: Baseline, Period A, Weeks 4, 8, and 11, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52
Percent Change From Baseline in PASI Score Over Time
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis).
Time frame: Baseline, Period A, Weeks 4, 8, 11 and 16, Period C, Weeks 0 and 16, Period D, Weeks 0, 16, 28, 40 and 52
Change From Baseline in CDLQI Over Time
The Children's Dermatology Life Quality Index (CDLQI) is a 10-item questionnaire to measure the quality of life in children aged from 4 to 16 years. Each question is scored from 0 (not at all) to 3 (very much). The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
Time frame: Baseline, Period A, Weeks 4, and 8, Period C, Weeks 0 and 4, Period D, Weeks 0, 11, 28, and 52
Percentage of Participants With CDLQI = 0 Over Time
The Children's Dermatology Life Quality Index (CDLQI) is a 10-item questionnaire to measure the quality of life in children aged from 4 to 16 years. Each question is scored from 0 (not at all) to 3 (very much). The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired and a score of 0 indicates no impairment in quality of life.
Time frame: Period A, Weeks 4, 8 and 16, Period C, Weeks 0 and 4, Period D, Weeks 0, 11, 28, and 52
Time to PASI 50/75/90/100 Response in Period A
Participants who did not have a response during Period A were censored.
Time frame: Period A, 16 weeks
Change From Baseline in PedsQL Over Time
The PedsQL Measurement Model measures health-related quality of life (HRQOL) in children and adolescents. The 23-item PedsQL Generic Core Scale includes Physical, Emotional, Social, School Functioning dimensions. Each item is scored from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL; the total score therefore ranges from 0 (worst) to 100 (best).
Time frame: Baseline, Period A, Weeks 4 and 8, Period C, Weeks 0 and 4, Period D, Weeks 0, 11, 28, and 52
Change From Baseline in the Children's Depression Inventory: Short (CDI:S)
The CDI:S is a short 10-item self-rated symptom-oriented scale used to screen for depressive symptoms. CDI:S scores range from 0 to 100, with a lower score indicating fewer depressive symptoms.
Time frame: Baseline, Period A, Weeks 4, 8, and 16
Participants were enrolled at 38 sites in Belgium, Canada, Chile, Czech Republic, Germany, Hungary, Italy, Mexico, Netherlands, Poland, Spain, Switzerland, and Turkey.
| Milestone | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Started | 37 | 39 | 38 |
| Entered period b | 13 | 18 | 23 |
| Entered period c | 8 | 11 | 19 |
| Entered period d | 36 | 36 | 36 |
| Completed | 34 | 26 | 30 |
| Not completed | 3 | 13 | 8 |
| Withdrew: Adverse event | 1 | 0 | 1 |
| Withdrew: Lack of efficacy | 1 | 9 | 4 |
| Withdrew: Clearing of psoriatic lesions | 1 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 2 |
| Withdrew: Loss of disease control | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in PASI score at Week 16.
| percentage of participants | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 75 Response at Week 16 | 32.4 | 43.6 | 57.9 |
The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: * 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; * 1 (Minimal): Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation; * 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; * 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; * 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; * 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) or minimal (1) is reported.
| percentage of participants | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Percentage of Participants Achieving a Physician's Global Assessment of Disease Activity (PGA) of "Cleared" (0) or "Minimal" (1) at Week 16 | 40.5 | 41.0 | 60.5 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 90 response is at least a 90% reduction (improvement) from Baseline in PASI score at Week 16.
| percentage of participants | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Percentage of Participants Who Achieved a PASI 90 Response at Week 16 | 21.6 | 30.8 | 28.9 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 100 response is a 100% reduction (improvement) from Baseline in PASI score at Week 16.
| percentage of participants | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Percentage of Participants Who Achieved a PASI 100 Response at Week 16 | 2.7 | 10.3 | 18.4 |
The Children's Dermatology Life Quality Index (CDLQI) is a 10-item questionnaire to measure the quality of life in children aged from 4 to 16 years. Each question is scored from 0 (not at all) to 3 (very much). The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
| units on a scale | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Change From Baseline in the Children's Dermatology Life Quality Index (CDLQI) Score at Week 16 | -5.0 ± 7.11 | -4.9 ± 6.16 | -6.6 ± 6.22 |
The PedsQL Measurement Model measures health-related quality of life (HRQOL) in children and adolescents. The 23-item PedsQL Generic Core Scale includes Physical, Emotional, Social, School Functioning dimensions. Each item is scored from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL; the total score therefore ranges from 0 (worst) to 100 (best).
| units on a scale | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Change From Baseline in the Pediatric Quality of Life Inventory (PedsQL) Score at Week 16 | 1.9 ± 10.41 | 9.5 ± 12.25 | 10.8 ± 15.38 |
The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; 1 (Minimal): Occasional fine scale over \< 5% of lesions, faint erythema, minimal plaque elevation; 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) or minimal (1) is reported.
| percentage of participants | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Percentage of Participants Achieving a PGA of "Cleared" (0) or "Minimal" (1) Upon Re-Treatment in Period C | 62.5 | 27.3 | 52.6 |
Loss of disease control was defined as a worsening of PGA scores in comparison to Week 16 of Period A by at least 2 grades after treatment withdrawal. The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. Scores range from 0 (no evidence of scaling, erythema, or plaque elevation) to 5 (very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation). Participants who did not lose disease control in period B continued off drug into period D and were observed off-drug until they finally lost disease control or until the end of the 52 weeks of period D.
| days | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Time to Loss of Disease Control for Participants Who Entered Period B | 184 (84 to 335) | 217 (56 to 551) | 118 (79 to 194) |
The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; 1 (Minimal): Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation; 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) or minimal (1) is reported.
| percentage of participants | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Period A, Week 4 | 8.1 | 20.5 | 28.9 |
| Period A, Week 8 | 8.1 | 35.9 | 44.7 |
| Period A, Week 11 | 18.9 | 30.8 | 47.4 |
| Period C, Week 0 | 0.0 | 0.0 | 0.0 |
| Period C, Week 16 | 62.5 | 27.3 | 52.6 |
| Period D, Week 0 | 30.6 | 19.4 | 38.9 |
| Period D, Week 16 | 77.8 | 38.9 | 50.0 |
| Period D, Week 28 | 69.4 | 50.0 | 63.9 |
| Period D, Week 40 | 69.4 | 50.0 | 61.1 |
| Period D, Week 52 | 75.0 | 50.0 | 55.6 |
The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; 1 (Minimal): Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation; 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) is reported.
| percentage of participants | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Period A, Week 4 | 0.0 | 2.6 | 2.6 |
| Period A, Week 8 | 0.0 | 12.8 | 5.3 |
| Period A, Week 11 | 0.0 | 10.3 | 10.5 |
| Period A, Week 16 | 8.1 | 12.8 | 18.4 |
| Period C, Week 0 | 0.0 | 0.0 | 0.0 |
| Period C, Week 16 | 25.0 | 9.1 | 15.8 |
| Period D, Week 0 | 8.3 | 5.6 | 11.1 |
| Period D, Week 16 | 25.0 | 11.1 | 25.0 |
| Period D, Week 28 | 33.3 | 16.7 | 22.2 |
| Period D, Week 40 | 33.3 | 16.7 | 27.8 |
| Period D, Week 52 | 41.7 | 25.0 | 25.0 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 50 response is at least a 50% reduction (improvement) from Baseline in PASI score.
| percentage of participants | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Period A, Week 4 | 16.2 | 41.0 | 52.6 |
| Period A, Week 8 | 40.5 | 56.4 | 65.8 |
| Period A, Week 11 | 51.4 | 61.5 | 71.1 |
| Period A, Week 16 | 54.1 | 66.7 | 78.9 |
| Period C, Week 0 | 62.5 | 90.9 | 52.6 |
| Period C, Week 16 | 87.5 | 90.9 | 89.5 |
| Period D, Week 0 | 52.8 | 63.9 | 75.0 |
| Period D, Week 16 | 91.7 | 69.4 | 88.9 |
| Period D, Week 28 | 88.9 | 72.2 | 86.1 |
| Period D, Week 40 | 91.7 | 63.9 | 83.3 |
| Period D, Week 52 | 91.7 | 66.7 | 77.8 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 75 response is at least a 75% reduction (improvement) from Baseline in PASI score.
| percentage of participants | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Period A, Week 4 | 0.0 | 15.4 | 23.7 |
| Period A, Week 8 | 13.5 | 38.5 | 47.4 |
| Period A, Week 11 | 21.6 | 43.6 | 60.5 |
| Period C, Week 0 | 37.5 | 18.2 | 21.1 |
| Period C, Week 16 | 75.0 | 54.5 | 78.9 |
| Period D, Week 0 | 30.6 | 27.8 | 50.0 |
| Period D, Week 16 | 86.1 | 50.0 | 61.1 |
| Period D, Week 28 | 80.6 | 58.3 | 77.8 |
| Period D, Week 40 | 77.8 | 52.8 | 75.0 |
| Period D, Week 52 | 86.1 | 47.2 | 72.2 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 90 response is at least a 90% reduction (improvement) from Baseline in PASI score.
| percentage of participants | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Period A, Week 4 | 0.0 | 5.1 | 5.3 |
| Period A, Week 8 | 2.7 | 20.5 | 23.7 |
| Period A, Week 11 | 2.7 | 28.2 | 28.9 |
| Period C, Week 0 | 0.0 | 0.0 | 10.5 |
| Period C, Week 16 | 62.5 | 27.3 | 57.9 |
| Period D, Week 0 | 25.0 | 16.7 | 36.1 |
| Period D, Week 16 | 63.9 | 36.1 | 38.9 |
| Period D, Week 28 | 55.6 | 33.3 | 41.7 |
| Period D, Week 40 | 55.6 | 36.1 | 47.2 |
| Period D, Week 52 | 66.7 | 33.3 | 44.4 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 100 response is a 100% reduction (improvement) from Baseline in PASI score.
| percentage of participants | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Period A, Week 4 | 0.0 | 0.0 | 2.6 |
| Period A, Week 8 | 0.0 | 5.1 | 5.3 |
| Period A, Week 11 | 0.0 | 5.1 | 10.5 |
| Period C, Week 0 | 0.0 | 0.0 | 0.0 |
| Period C, Week 16 | 25.0 | 9.1 | 15.8 |
| Period D, Week 0 | 8.3 | 5.6 | 11.1 |
| Period D, Week 16 | 13.9 | 11.1 | 25.0 |
| Period D, Week 28 | 27.8 | 13.9 | 19.4 |
| Period D, Week 40 | 30.6 | 13.9 | 22.2 |
| Period D, Week 52 | 41.7 | 25.0 | 22.2 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis).
| percent change | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Period A, Week 4 | -14.0 ± 36.71 | -36.9 ± 38.62 | -48.3 ± 33.96 |
| Period A, Week 8 | -30.6 ± 45.89 | -48.8 ± 44.74 | -60.3 ± 35.98 |
| Period A, Week 11 | -36.6 ± 51.69 | -51.4 ± 50.19 | -62.8 ± 38.02 |
| Period A, Week 16 | -42.8 ± 54.24 | -52.4 ± 51.79 | -65.6 ± 39.44 |
| Period C, Week 0 | -59.0 ± 20.61 | -65.3 ± 12.16 | -45.8 ± 39.64 |
| Period C, Week 16 | -87.1 ± 16.47 | -74.5 ± 17.79 | -69.3 ± 69.79 |
| Period D, Week 0 | -41.8 ± 54.99 | -46.8 ± 49.27 | -61.5 ± 42.96 |
| Period D, Week 16 | -82.3 ± 31.38 | -66.9 ± 33.51 | -74.5 ± 37.44 |
| Period D, Week 28 | -81.0 ± 35.86 | -65.8 ± 36.99 | -81.5 ± 22.06 |
| Period D, Week 40 | -83.0 ± 31.94 | -64.6 ± 37.46 | -82.1 ± 23.99 |
| Period D, Week 52 | -86.3 ± 28.92 | -58.7 ± 53.21 | -80.1 ± 24.17 |
The Children's Dermatology Life Quality Index (CDLQI) is a 10-item questionnaire to measure the quality of life in children aged from 4 to 16 years. Each question is scored from 0 (not at all) to 3 (very much). The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
| units on a scale | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Period A, Week 4 | -2.9 ± 5.24 | -3.9 ± 5.22 | -4.9 ± 5.80 |
| Period A, Week 8 | -4.0 ± 6.44 | -4.1 ± 6.29 | -5.5 ± 5.66 |
| Period C, Week 0 | -6.1 ± 4.55 | -4.7 ± 9.08 | -6.1 ± 6.92 |
| Period C, Week 4 | -9.8 ± 3.92 | -5.5 ± 7.24 | -7.0 ± 6.63 |
| Period D, Week 0 | -5.6 ± 7.55 | -5.5 ± 5.95 | -6.8 ± 6.70 |
| Period D, Week 11 | -8.5 ± 5.37 | -6.8 ± 7.07 | -7.4 ± 6.21 |
| Period D, Week 28 | -8.3 ± 5.93 | -6.8 ± 7.91 | -8.4 ± 6.72 |
| Period D, Week 52 | -8.4 ± 6.08 | -6.6 ± 8.12 | -8.2 ± 6.75 |
The Children's Dermatology Life Quality Index (CDLQI) is a 10-item questionnaire to measure the quality of life in children aged from 4 to 16 years. Each question is scored from 0 (not at all) to 3 (very much). The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired and a score of 0 indicates no impairment in quality of life.
| percentage of participants | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Period A, Week 4 | 5.4 | 5.1 | 10.5 |
| Period A, Week 8 | 10.8 | 12.8 | 5.3 |
| Period A, Week 16 | 10.8 | 20.5 | 23.7 |
| Period C, Week 0 | 0.0 | 36.4 | 21.1 |
| Period C, Week 4 | 12.5 | 36.4 | 31.6 |
| Period D, Week 0 | 16.7 | 22.2 | 27.8 |
| Period D, Week 11 | 25.0 | 16.7 | 33.3 |
| Period D, Week 28 | 30.6 | 22.2 | 30.6 |
| Period D, Week 52 | 41.7 | 16.7 | 33.3 |
Participants who did not have a response during Period A were censored.
| days | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| PASI 50 | 76 (56 to 112) | 55 (28 to 115) | 30 (28 to 77) |
| PASI 75 | 116 (111 to NA) | 107 (56 to NA) | 59 (53 to NA) |
| PASI 90 | NA (112 to NA) | NA (78 to NA) | NA (76 to NA) |
| PASI 100 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
The PedsQL Measurement Model measures health-related quality of life (HRQOL) in children and adolescents. The 23-item PedsQL Generic Core Scale includes Physical, Emotional, Social, School Functioning dimensions. Each item is scored from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL; the total score therefore ranges from 0 (worst) to 100 (best).
| units on a scale | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Period A, Week 4 | -0.8 ± 11.75 | 4.9 ± 13.80 | 8.1 ± 11.95 |
| Period A, Week 8 | 0.5 ± 10.18 | 7.0 ± 13.16 | 8.8 ± 15.45 |
| Period C, Week 0 | 3.0 ± 10.45 | 8.9 ± 25.35 | 14.2 ± 20.25 |
| Period C, Week 4 | 5.2 ± 11.08 | 11.6 ± 25.19 | 16.3 ± 17.35 |
| Period D, Week 0 | 2.3 ± 10.93 | 9.4 ± 16.90 | 10.5 ± 15.86 |
| Period D, Week 11 | 5.4 ± 10.36 | 12.8 ± 19.03 | 12.0 ± 16.13 |
| Period D, Week 28 | 8.0 ± 13.40 | 14.5 ± 20.19 | 13.1 ± 16.23 |
| Period D, Week 52 | 8.6 ± 13.93 | 14.0 ± 20.40 | 13.8 ± 15.36 |
The CDI:S is a short 10-item self-rated symptom-oriented scale used to screen for depressive symptoms. CDI:S scores range from 0 to 100, with a lower score indicating fewer depressive symptoms.
| units on a scale | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg |
|---|---|---|---|
| Period A, Week 4 | 0.6 ± 8.85 | -1.0 ± 6.64 | -3.6 ± 5.86 |
| Period A, Week 8 | 0.2 ± 5.26 | -1.5 ± 7.52 | -1.6 ± 5.52 |
| Period A, Week 16 | -2.0 ± 5.88 | -3.3 ± 8.12 | -2.3 ± 6.29 |
Collected over Period A - up to 16 weeks; Period B - up to 36 weeks; Period C - up to 16 weeks; Period D - up to 52 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Methotrexate | — | 0/37 (0%) | 23/37 (62.2%) |
| Adalimumab 0.4 mg/kg | — | 3/39 (7.7%) | 27/39 (69.2%) |
| Adalimumab 0.8 mg/kg | — | 0/38 (0%) | 23/38 (60.5%) |
| Period B: MTX/No Treatment | — | 0/13 (0%) | 6/13 (46.2%) |
| Period B: ADA 0.4 mg/kg/No Treatment | — | 0/18 (0%) | 6/18 (33.3%) |
| Period B: ADA 0.8 mg/kg/No Treatment | — | 1/23 (4.3%) | 6/23 (26.1%) |
| Period C: Adalimumab 0.4 mg/kg | — | 0/11 (0%) | 5/11 (45.5%) |
| Period C: Adalimumab 0.8 mg/kg | — | 0/27 (0%) | 16/27 (59.3%) |
| Period D: Adalimumab 0.4 mg/kg | — | 0/13 (0%) | 8/13 (61.5%) |
| Period D: Adalimumab 0.8 mg/kg | — | 5/87 (5.7%) | 64/87 (73.6%) |
| Event | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg | Period B: MTX/No Treatment | Period B: ADA 0.4 mg/kg/No Treatment | Period B: ADA 0.8 mg/kg/No Treatment | Period C: Adalimumab 0.4 mg/kg | Period C: Adalimumab 0.8 mg/kg | Period D: Adalimumab 0.4 mg/kg | Period D: Adalimumab 0.8 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Haemorrhagic Ovarian CystReproductive system and breast disorders | 0/37 | 0/39 | 0/38 | 0/13 | 0/18 | 1/23 | 0/11 | 0/27 | 0/13 | 0/87 |
| Gastrointestinal InfectionInfections and infestations | 0/37 | 1/39 | 0/38 | 0/13 | 0/18 | 0/23 | 0/11 | 0/27 | 0/13 | 0/87 |
| Hand FractureInjury, poisoning and procedural complications | 0/37 | 1/39 | 0/38 | 0/13 | 0/18 | 0/23 | 0/11 | 0/27 | 0/13 | 0/87 |
| AgitationPsychiatric disorders | 0/37 | 1/39 | 0/38 | 0/13 | 0/18 | 0/23 | 0/11 | 0/27 | 0/13 | 0/87 |
| Chest PainGeneral disorders | 0/37 | 0/39 | 0/38 | 0/13 | 0/18 | 0/23 | 0/11 | 0/27 | 0/13 | 1/87 |
| FallInjury, poisoning and procedural complications | 0/37 | 0/39 | 0/38 | 0/13 | 0/18 | 0/23 | 0/11 | 0/27 | 0/13 | 1/87 |
| Tendon InjuryInjury, poisoning and procedural complications | 0/37 | 0/39 | 0/38 | 0/13 | 0/18 | 0/23 | 0/11 | 0/27 | 0/13 | 1/87 |
| Eye NaevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/37 | 0/39 | 0/38 | 0/13 | 0/18 | 0/23 | 0/11 | 0/27 | 0/13 | 1/87 |
| Rash Maculo-PapularSkin and subcutaneous tissue disorders | 0/37 | 0/39 | 0/38 | 0/13 | 0/18 | 0/23 | 0/11 | 0/27 | 0/13 | 1/87 |
| Event | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg | Period B: MTX/No Treatment | Period B: ADA 0.4 mg/kg/No Treatment | Period B: ADA 0.8 mg/kg/No Treatment | Period C: Adalimumab 0.4 mg/kg | Period C: Adalimumab 0.8 mg/kg | Period D: Adalimumab 0.4 mg/kg | Period D: Adalimumab 0.8 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 7/37 | 10/39 | 8/38 | 0/13 | 1/18 | 4/23 | 1/11 | 5/27 | 3/13 | 25/87 |
| HeadacheNervous system disorders | 4/37 | 7/39 | 6/38 | 1/13 | 2/18 | 1/23 | 0/11 | 3/27 | 1/13 | 22/87 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/37 | 4/39 | 1/38 | 0/13 | 2/18 | 0/23 | 2/11 | 1/27 | 1/13 | 4/87 |
| Upper Respiratory Tract InfectionInfections and infestations | 6/37 | 4/39 | 2/38 | 0/13 | 2/18 | 1/23 | 0/11 | 3/27 | 0/13 | 13/87 |
| NauseaGastrointestinal disorders | 4/37 | 3/39 | 2/38 | 0/13 | 0/18 | 0/23 | 0/11 | 2/27 | 1/13 | 10/87 |
| Back PainMusculoskeletal and connective tissue disorders | 0/37 | 1/39 | 2/38 | 0/13 | 0/18 | 0/23 | 0/11 | 3/27 | 0/13 | 1/87 |
| Abdominal PainGastrointestinal disorders | 4/37 | 1/39 | 1/38 | 0/13 | 0/18 | 0/23 | 0/11 | 0/27 | 0/13 | 4/87 |
| InfluenzaInfections and infestations | 0/37 | 0/39 | 1/38 | 0/13 | 0/18 | 0/23 | 0/11 | 0/27 | 0/13 | 9/87 |
| FatigueGeneral disorders | 2/37 | 4/39 | 0/38 | 0/13 | 0/18 | 0/23 | 0/11 | 2/27 | 0/13 | 4/87 |
| GastroenteritisInfections and infestations | 3/37 | 0/39 | 2/38 | 0/13 | 0/18 | 0/23 | 1/11 | 0/27 | 0/13 | 1/87 |
Intent-to-treat population included all randomized participants
| Age, Continuous(years) | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg | Total |
|---|---|---|---|---|
| Mean | 13.4 ± 3.49 | 12.6 ± 4.43 | 13.0 ± 3.29 | 13.0 ± 3.76 |
| Sex: Female, Male(Participants) | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg | Total |
|---|---|---|---|---|
| Female | 26 | 18 | 21 | 65 |
| Male | 11 | 21 | 17 | 49 |
| Race/Ethnicity, Customized(Participants) | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg | Total |
|---|---|---|---|---|
| White | 34 | 34 | 35 | 103 |
| Black | 0 | 0 | 0 | 0 |
| Asian | 2 | 2 | 1 | 5 |
| American Indian/Alaska Native | 0 | 0 | 0 | 0 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 0 |
| Other | 1 | 2 | 2 | 5 |
| Mutli Race | 0 | 1 | 0 | 1 |
| Psoriasis Area and Severity Index (PASI)(units on a scale) | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg | Total |
|---|---|---|---|---|
| Mean | 19.2 ± 10.02 | 16.9 ± 5.76 | 18.9 ± 10.03 | 18.3 ± 8.78 |
| Physician's Global Assessment of Psoriasis(Participants) | Methotrexate | Adalimumab 0.4 mg/kg | Adalimumab 0.8 mg/kg | Total |
|---|---|---|---|---|
| Cleared | 0 | 0 | 0 | 0 |
| Minimal | 0 | 1 | 0 | 1 |
| Mild | 1 | 3 | 3 | 7 |
| Moderate | 19 | 18 | 17 | 54 |
| Marked | 17 | 15 | 17 | 49 |
| Severe | 0 | 2 | 1 | 3 |
No study locations are listed for this record.
The record gives a start of Dec 2010, a primary completion of Dec 2013 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
AbbVie (prior sponsor, Abbott) →